2-year data on cell therapy for degenerative disc disease is out: 5 things to know


Orthobiologics company DiscGenics shared data supporting its IDCT (rebonuputemcel) allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease.

Five things to know:

1. A randomized blind study evaluated IDCT in patients over two years, according to a Jan. 23 news release. It is the first human clinical study of IDCT.

2. The study found high dose IDCT met key safety and efficacy endpoints and led to "statistically significant" improvements in lower back pain, function and disc volume after one injection into the intervertebral disc.

3. Clinical improvements remained after six months, one year, 18 months and two years.

4. Low doses of IDCT saw "inconsistent" trends in clinical outcomes, DiscGenics said. 

5. Patients in the high dose IDCT group were the only ones to show a decrease in both opioid and NSAID use.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers